Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 7:20 AMYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Biocon Biologics receives EMA Committee positive opinions for Biosimilar Denosumab for bone health Ruchika Sharma26 April 2025 7:06 AMBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the Committee...
Biocon Biologics secures market entry date for ophthalmology drug Yesafili in US Ruchika Sharma15 April 2025 10:48 AMAdditionally, Biocon Biologics secured a settlement agreement in Canada with Bayer and Regeneron Pharma for launch of YESAFILI no later than July 1,...
Biocon Biologics gets USFDA nod for cancer drug Jobevne Ruchika Sharma10 April 2025 7:09 AMBengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the U.S. Food and Drug Administration (U.S. FDA) has...
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics Ruchika Sharma8 March 2025 8:00 AMBengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced the successful results...
Biocon Biologics, Civica join hands to expand Insulin Aspart access in US Ruchika Sharma7 March 2025 6:00 AMCivica will commercialize the medicine for patients in the United States, after completion of development work and clinical trials.
Biocon Biologics unveils Yesintek biosimilar to Stelara in US Ruchika Sharma25 Feb 2025 7:01 AMYESINTEK will be available in all the same formulations currently provided by Stelara.
Biocon Biologics Yesintek gets European Commission approval for plaque psoriasis, psoriatic arthritis Ruchika Sharma18 Feb 2025 10:12 AMBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
Biocon Biologics Malaysia site classified as VAI by USFDA Ruchika Sharma13 Jan 2025 6:00 AMBengaluru: Biocon has announced that the U.S. Food and Drug Administration (FDA) has classified Biocon Biologics' Insulins facilities in...
Biocon Biologics to present at 43rd Annual JP Morgan Healthcare Conference Ruchika Sharma10 Jan 2025 8:00 AMKarnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, will present at the 43rd Annual J.P....
Biocon Biologics gets Japenese nod for Psoriasis Vulgaris injection Ustekinumab BS Ruchika Sharma7 Jan 2025 7:45 AMBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the...
Approval of Biocon Biologics Yesintek recommended by EMA Committee Ruchika Sharma16 Dec 2024 6:00 AMBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the European...
